



OPEN ACCESS

EDITED BY

Sergei Covantsev,
S.P. Botkin Clinical Hospital, Russia

REVIEWED BY

Alexandr Ceasovschi,
Grigore T. Popa University of Medicine and
Pharmacy, Romania
Oleg Arnaut,
Nicolae Testemitanu State University of
Medicine and Pharmacy, Moldova
Anna Bumbu,
S.P. Botkin Clinical Hospital, Russia

*CORRESPONDENCE

Narongkorn Saiphoklang
✉ m_narongkorn@hotmail.com

RECEIVED 06 October 2023

ACCEPTED 13 December 2023

PUBLISHED 11 January 2024

CITATION

Sriprasart T, Saiphoklang N, Kawamatawong T,
Boonsawat W, Mitthamsiri W,
Chirakalwasan N, Chiewchalermisri C,
Athipongarporn A, Kamalaporn H,
Kornthatchapong K, Kulpraneet M,
Sompornrattanaphan M, Oer-Areemitr N,
Rerkpattanapipat T, Silairatana S,
Thawanaphong S, Gaensan T, Jirakran K, and
Poachanukoon O (2024) Allergic rhinitis and
other comorbidities associated with asthma
control in Thailand.
Front. Med. 10:1308390.
doi: 10.3389/fmed.2023.1308390

COPYRIGHT

© 2024 Sriprasart, Saiphoklang,
Kawamatawong, Boonsawat, Mitthamsiri,
Chirakalwasan, Chiewchalermisri,
Athipongarporn, Kamalaporn,
Kornthatchapong, Kulpraneet,
Sompornrattanaphan, Oer-Areemitr,
Rerkpattanapipat, Silairatana, Thawanaphong,
Gaensan, Jirakran and Poachanukoon. This is
an open-access article distributed under the
terms of the [Creative Commons Attribution
License \(CC BY\)](https://creativecommons.org/licenses/by/4.0/). The use, distribution or
reproduction in other forums is permitted,
provided the original author(s) and the
copyright owner(s) are credited and that the
original publication in this journal is cited, in
accordance with accepted academic
practice. No use, distribution or reproduction
is permitted which does not comply with
these terms.

Allergic rhinitis and other comorbidities associated with asthma control in Thailand

Thitiwat Sriprasart¹, Narongkorn Saiphoklang^{2*},
Theerasuk Kawamatawong³, Watchara Boonsawat⁴,
Wat Mitthamsiri⁵, Naricha Chirakalwasan^{1,6},
Chirawat Chiewchalermisri⁷, Athipat Athipongarporn⁸,
Harutai Kamalaporn⁹, Kumpol Kornthatchapong¹⁰,
Manaphol Kulpraneet¹¹, Mongkhon Sompornrattanaphan¹²,
Nittha Oer-Areemitr¹³, Ticha Rerkpattanapipat¹⁴,
Santi Silairatana¹⁵, Sarita Thawanaphong¹, Thanate Gaensan¹⁶,
Ketsupar Jirakran¹⁷ and Orapan Poachanukoon¹⁸ on behalf of
Thai Asthma Council and Association (TAC)¹Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Faculty of
Medicine, Chulalongkorn University, King Chulalongkorn Memorial Hospital, Thai Red Cross Society,
Bangkok, Thailand, ²Division of Pulmonary and Critical Care Medicine, Department of Internal
Medicine, Faculty of Medicine, Thammasat University, Pathum Thani, Thailand, ³Division of Pulmonary
and Critical Care Medicine, Department of Internal Medicine, Faculty of Medicine, Ramathibodi
Hospital, Mahidol University, Bangkok, Thailand, ⁴Department of Medicine, Faculty of Medicine, Khon
Kaen University, Khon Kaen, Thailand, ⁵Allergy and Clinical Immunology Division, Department of
Medicine, Phramongkutklao Hospital, Bangkok, Thailand, ⁶Excellence Center for Sleep Disorders, Thai
Red Cross Society, Bangkok, Thailand, ⁷Department of Medicine, Panyanantaphikhu Chonprathan
Medical Center, Srinakharinwirot University, Nonthaburi, Thailand, ⁸Department of Pediatrics, Phra
Nakhon Si Ayutthaya Hospital, Phra Nakhon Si Ayutthaya, Thailand, ⁹Division of Pediatric
Pulmonology, Department of Pediatrics, Faculty of Medicine, Ramathibodi Hospital, Mahidol
University, Bangkok, Thailand, ¹⁰Department of Emergency Medicine, Faculty of Medicine, Thammasat
University, Pathum Thani, Thailand, ¹¹Division of Pulmonary and Critical Care, Department of
Medicine, Srinakharinwirot University, Bangkok, Thailand, ¹²Division of Allergy and Clinical Immunology,
Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand,
¹³Division of Pulmonary and Critical Care Medicine, Ekachai Hospital, Samut Sakhon, Thailand,
¹⁴Allergy Immunology and Rheumatology Division, Department of Medicine, Faculty of Medicine,
Ramathibodi Hospital, Mahidol University, Bangkok, Thailand, ¹⁵Division of Pulmonary Medicine and
Pulmonary Critical Care, Department of Medicine, Faculty of Medicine Vajira Hospital,
Navamindradhiraj University, Bangkok, Thailand, ¹⁶Department of Family Medicine, Faculty of
Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand, ¹⁷Center of Excellence for
Maximizing Children's Developmental Potential, Department of Pediatrics, Faculty of Medicine,
Chulalongkorn University, Bangkok, Thailand, ¹⁸Center of Excellence for Allergy, Asthma and
Pulmonary Diseases, Thammasat University, Pathum Thani, Thailand**Background:** Asthma and allergic rhinitis (AR) can coexist and cause disabilities.
This study aimed to assess the association between AR, asthma control, asthma-
related quality of life, and other comorbidities.**Methods:** A cross-sectional study was conducted in adults with asthma in
six hospitals in Thailand. The outcomes were association of asthma control
assessed by the asthma control test (ACT), AR, and asthma comorbidities.
Not-well-controlled asthma was defined as ACT scores ≤ 22 . The severity of
AR was determined by visual analog scale (VAS). Severe AR was defined as VAS
 ≥ 5 . Asthma-related quality of life (AQLQ), comorbidities, and total IgE were
recorded.**Results:** A total of 682 asthmatic patients were included. Median (IQR) age was
58.0 (47.0–64.0) years. 69.9% were female. Not-well-controlled asthma was

present in 44.7%. The prevalence of AR was 86.1%. Moderate/severe persistent AR was diagnosed in 21.7% and severe AR was diagnosed in 30.2% of the patients. Inhaled corticosteroid-containing regimens were prescribed in 97.7% of patients. Intranasal corticosteroid and antihistamine were prescribed in 65.7 and 31.7%, respectively. Patients with not-well-controlled asthma had higher body mass index, VAS scores, proportions of pollution exposure, aeroallergen sensitization, severe AR, nasal polyp, urticaria, food allergy, gastroesophageal reflux disease, depression and anxiety, peptic ulcer, and asthma exacerbations, but younger age, lower AQLQ scores, and lower FEV₁. Correlation was found between AR severity and ACT ($r = -0.461$, $p < 0.001$), AQLQ ($r = -0.512$, $p < 0.001$), and total IgE ($r = 0.246$, $p < 0.023$). Multiple regression analysis revealed that ACT, AQLQ, and percentage of FEV₁/FVC were significantly associated with severe AR.

Conclusion: Allergic rhinitis is prevalent in Thai asthmatic patients. AR severity is associated with asthma control, quality of life, and pulmonary function. Comprehensive care is essential for patients with uncontrolled asthma, particularly when coexisting with conditions.

KEYWORDS

ACT, asthma, asthma control test, allergic rhinitis, comorbidities, IgE, quality of life, Thailand

1 Introduction

Asthma is a heterogeneous disease, usually characterized by chronic airway inflammation. It is defined by the history of respiratory symptoms, such as wheeze, shortness of breath, chest tightness and cough that vary over time and in intensity, together with variable expiratory airflow limitation (1). Asthma and allergic rhinitis (AR) are characterized by chronic airway inflammation and components of other diseases. Asthma presents with variable respiratory symptoms and airflow limitation (2). AR presents with nasal congestion, sneezing, running nose, and ocular itch, which affect the patient's quality of life (3). The majority of asthmatic patients have pulmonary and extrapulmonary comorbidities. AR, a common comorbidity in patients with asthma, affects asthma outcomes (3, 4). The prevalence of AR in patients with and without asthma in the Asia Pacific region varies according to the definition and recruited population (5–11). In a systematic review, the worldwide prevalence of AR is 18.1% (ranging from 1.0 to 54.5%) (12). Prevalence of AR ranged from 3.5 to 54.5% for America, from 1.0 to 43.9% for Europe, and from 1.0 to 47.9% for Asia (12). AR and other asthma-related comorbidities increase clinical complexities and healthcare costs (11, 13). Despite recommendations of asthma management and effective medications, particularly inhaled corticosteroids (ICS), a substantial number of asthmatic patients have not controlled their diseases. Ultimately, not-well-controlled asthma affects patient quality of life and leads to exacerbations and hospitalizations (13, 14).

An epidemiological survey of physician management of AR coexisting with asthma in the Asia Pacific region including Thailand revealed many problems (14, 15). Pulmonary and extrapulmonary comorbidities with asthma have been addressed for several decades (16). Obesity, obstructive sleep apnea (OSA), and gastroesophageal reflux disease (GERD) coexist in asthmatic patients (16–19). Comorbidities, including AR, contribute to risk factors and share inflammatory pathways with asthma. Both AR and asthma are

inflammatory diseases and their inflammatory mechanisms are similar in that they are characterized by an inflammatory infiltrate made up of eosinophils, T cells, and mast cells that release several mediators, chemokines and cytokines, local and systemic IgE synthesis, and a systemic link via the bone marrow (20). These conditions drive the development of asthma and aggravate asthma control. Global and national asthma management guidelines recommend appropriate diagnosis and management of comorbidities. The interaction of asthma control, comorbidities, and health-related quality of life has never been systematically explored.

The aim of this study was to assess the association between AR and asthma control in adults in six medical centers in Bangkok and other provinces of Thailand. In addition, asthma-related quality of life and associations between asthma control and other comorbidities were assessed.

2 Methods

2.1 Study design and subjects

A cross-sectional study was conducted in asthma outpatient clinics from six tertiary medical centers in Thailand between December 2021 and December 2022. Consecutive asthmatic patients, aged 18 years or older and diagnosed according to the Global Initiative for Asthma strategy, were recruited from six university teaching hospitals.

Ethical approval for this study was obtained from the institutional committee on human research in each site of patient recruitment, in full compliance with international guidelines such as the Declaration of Helsinki, the Belmont Report, CIOMS Guidelines, and the International Conference on Harmonization-Good Clinical Practice (ICH-GCP). All methods were performed in accordance with these guidelines and regulations. All participants provided written informed consent.

2.2 Data collection

Allergic rhinitis was diagnosed by a clinician and by International Study of Asthma and Allergies in Childhood (ISAAC)-based questionnaires inquiring about the prevalence of AR and ocular symptoms (5, 8). The diagnosis of AR was made when the history and physical findings were consistent with an allergic cause (e.g., clear rhinorrhea, pale discoloration of nasal mucosa, and red and watery eyes) and one or more of the following symptoms: nasal congestion, runny nose, itchy nose, or sneezing. The severity of AR was assessed by a visual analog scale (VAS) ranging from 0 (no symptoms) to 10 (very severe symptoms) (3). Severe AR was defined as VAS ≥ 5 .

Patient demographics and clinical characteristics including age, sex, age at initial asthma diagnosis, body mass index (BMI), smoking history, and indoor biomass and pollution exposure were recorded. Asthma exacerbations requiring emergency department (ED) visits in the past year and exacerbations requiring hospitalization in the past year were recorded. Current pharmacological and non-pharmacological treatments including bronchial thermoplasty were reviewed. Asthma medications including ICS, long-acting beta₂-agonists, long-acting muscarinic antagonists, oral theophylline, type 2 biologics, and oral low-dose prednisolone, and AR medications including intranasal corticosteroid and oral medications were recorded. The daily dose of ICS was expressed as the budesonide equivalent in micrograms per day (2). Asthmatic patients were divided into elderly (65 years or older) and younger groups (younger than 65 years).

The Thai version of the Asthma Control Test (ACTTM; scores from 5 to 25) was used to assess asthma control levels. Not-well-controlled asthma was defined as ACT ≤ 22 and uncontrolled asthma was defined as ACT ≤ 19 (21, 22). The Asthma Quality of Life Questionnaire (AQLQ) Thai version, 15-items with seven-point scale (scores from 15 to 105), was used to assess the asthma-related quality of life of patients (23, 24). Higher AQLQ scores indicated better quality of life. AR-related quality of life was assessed by the Rhinoconjunctivitis QoL Questionnaire (Rcq-36); 36 questions covering six domains (25).

Comorbidities including chronic rhinosinusitis, nasal polyps, OSA diagnosed by polysomnography, peptic ulcer, food allergy, aspirin hypersensitivity, atopic dermatitis, urticaria, diabetes, hypertension, obesity, coronary artery disease, and chronic kidney disease were assessed in the asthmatic patients and recorded. Disease-specific questionnaires for specific comorbidities were examined. Anxiety and depression were assessed using the Hospital Anxiety Depression Scale (HADS) questionnaire with subscales for both anxiety (HADS-A) and depression (HADS-D); scores ≥ 8 and ≥ 8 indicating anxiety and depression, respectively (26, 27). GERD was assessed by the Gastroesophageal Reflux Questionnaire (GerdQ); scores >9 suggesting GERD (28). A modified STOP-Bang questionnaire was used for assessing the risk of OSA; scores ≥ 3 suggesting risk for sleep apnea (29).

Spirometry was performed according to the American Thoracic Society and European Respiratory Society Standardization (30). Bronchodilator (BD) response test was done using salbutamol inhalation (total dose 400 μ g) and repeating spirometry 15 min later. Pre-BD and post-BD forced expiratory volume in 1 s (FEV₁), forced vital capacity (FVC), and FEV₁/FVC were recorded and expressed in liters (L), %predicted, or %. Complete blood counts including eosinophil counts, serum specific IgE and total IgE were recorded.

2.3 Statistics analysis

We hypothesized that the prevalence of severe AR in patients with not-well-controlled asthma in our study would be 50%. The sample size was calculated for a prevalence survey using 5% margin of error, 80% power, and a two-sided alpha of 0.05. Therefore, the estimated sample size would be 385. Data were expressed as number (%), mean $\pm$ standard deviation or median (interquartile range; IQR). Chi-squared test was used to compare categorical variables between the two groups. Independent sample *t*-test was used to compare continuous variables with normal distributions between the two groups. The Mann–Whitney U test was used to compare between two independent groups on continuous variables with non-normal distributions. Pearson correlation was used for assessing the correlation between two independent continuous variables and presented as correlation coefficient (R). To determine factors associated with severe AR, we employed the logistic regression model with severe AR as the dependent variable. All independent variables—ACT, AQLQ, HADS-A, HADS-D, FEV₁, FEV₁/FVC, and total IgE—were entered into the regression model, followed by backward selection using a *p* value cutoff of 0.1. We report the regression coefficients along with 95% confidence interval, and corresponding *p* values. A two-sided value of *p* < 0.05 was considered statistically significant. Statistical analyses were performed using SPSS version 25.0 software (IBM Corp., Armonk, NY, United States).

3 Results

Six hundred eighty-two patients with asthma were included. Median (IQR) age was 58.0 (47.0–64.0) years. 69.8% were female. Pre-BD FEV₁ was 80.00 (67.00–91.47) %. Blood eosinophil counts were 227.70 (100.00–437.51) cells/ μ L. Aeroallergen sensitization was 20.7%. ACT was 23.00 (20.00–24.00). The asthma was controlled in 55.3% of patients whereas in 44.7% of patients it was not well-controlled. 13.8% of patients had history of asthma exacerbations. 97.7% of patients received regular ICS treatment (Table 1).

The prevalence of ISAAC-defined AR was 86.1%. Moderate/severe persistent AR was in 21.7% and severe AR was in 30.2% of patients. Intranasal corticosteroid and antihistamine were prescribed for AR treatment in 65.7 and 31.7% of patients (Table 2). Common comorbidities included hypertension (26.2%) and diabetes (10.7%), while the prevalence of coronary artery disease and chronic kidney disease was 2.8 and 2.5%, respectively. OSA was diagnosed in 12.0%, while STOP-Bang scores suggested a risk for sleep apnea in 11.0%. GERD was diagnosed by a clinician in 21.7% and by GerdQ in 1.9% (Table 2).

Patients with not-well-controlled asthma had significantly higher BMI, higher VAS scores for AR severity, and higher proportions of indoor pollution exposure, aeroallergen sensitization, severe AR, nasal polyp, urticaria, food allergy, GERD, depression and anxiety, peptic ulcer, and asthma exacerbations, but they were younger and they had lower total AQLQ scores and FEV₁ than patients with controlled asthma (Table 3). Moreover, a higher proportion of patients with not-well-controlled asthma had medium- to high-dose ICS treatment (Table 3).

Correlation was found between severity of AR and ACT ($r = -0.461$, $p < 0.001$), AQLQ ($r = -0.512$, $p < 0.001$), HADS-A scores

TABLE 1 Baseline characteristics of asthmatic patients.

Characteristics	Data (n = 682)
Age, years	58.0 (47.0–64.0)
Male/Female	205 (30.1)/477 (69.9)
Body mass index, kg/m ²	24.8 (22.4–28.1)
Age at initial asthma diagnosis ≤40 years	398 (58.4)
Smoking history	97 (14.2)
Indoor biomass exposure	126 (18.5)
Pre-BD FEV ₁ , L	1.99 (1.53–2.53)
Pre-BD FEV ₁ , % predicted	80.00 (67.00–91.47)
Pre-BD FEV ₁ /FVC, %	73.77 (64.49–81.39)
Blood eosinophil, cells/μL	227.70 (100.00–437.51)
Serum total IgE, IU/mL	155.00 (77.02–505.62)
Aeroallergen sensitization ^a	141 (20.7)
AQLQ, total scores	97.00 (83.00–105.00)
ACT, scores	23.00 (20.00–24.00)
Controlled asthma ^b	377 (55.3)
Not-well-controlled asthma ^c	305 (44.7)
History of asthma exacerbations	94 (13.8)
Exacerbation requiring ED visit in the past year	54 (7.9)
Exacerbation requiring hospitalization in the past year	17 (2.5)
ICS-containing therapy ^d	
No ICS or Intermittent ICS/formoterol	16 (2.3)
Regular low-dose ICS	315 (46.2)
Regular low-medium dose ICS	22 (3.2)
Regular medium ICS	201 (29.5)
Regular high-dose ICS	128 (18.8)
Add-on therapy	
LABA	632 (92.7)
LTRA	250 (36.7)
LAMA	112 (16.4)
Theophylline	45 (6.6)
Prednisolone	39 (5.7)
Bronchial thermoplasty	20 (2.9)
Type 2 biologics	7 (1.0)

Data shown as n (%) or median (IQR). ^aDefined as positive skin prick test or specific IgE.

^bDefined as ACT scores > 22. ^cDefined as ACT scores ≤ 22. ^dDaily ICS dose as budesonide equivalent (μg/day); low = 200–400, medium > 400–800, and high > 800. ACT, Asthma Control Test; AQLQ, Asthma Quality of Life Questionnaire; BD, Bronchodilator; ED, Emergency department; FEV₁, Forced expiratory volume in 1 s; FVC, Forced expiratory volume; ICS, Inhaled corticosteroid; IgE, Immunoglobulin E; kg, Kilogram; L, Liter; LABA, Long-acting beta2-agonist; LAMA, Long-acting muscarinic antagonist; LTRA, Leukotriene receptor antagonist; m, Meter.

($r = 0.357$, $p = 0.006$), HADS-D scores ($r = 0.401$, $p = 0.002$), and serum total IgE ($r = 0.246$, $p < 0.023$; Table 4). Spirometry parameters were not correlated to AR severity (Table 4). Multiple regression analysis revealed that ACT and AQLQ scores, along with percentage of FEV₁/FVC, were significantly associated with severe AR (Table 5).

Compared to male patients, female patients exhibited lower BMI, AQLQ scores, blood eosinophil level, and proportions of smoking

TABLE 2 Characteristics of allergic rhinitis and other asthma-related comorbidities.

Characteristics	Data (n = 682)
Allergic rhinitis	
AR ^a	540 (79.2)
AR by ISAAC criteria	587 (86.1)
ISAAC questionnaire: nose symptoms ever	577 (84.6)
ISAAC questionnaire: nose symptoms within 12 months	487 (71.4)
ISAAC questionnaire: nose with eye symptoms	285 (41.8)
ISAAC questionnaire: symptoms interfere with daily activity	275 (40.3)
Moderate/severe persistent AR by ARIA criteria	148 (21.7)
Severe AR ^b	206 (30.2)
VAS for AR severity, scores	2.0 (0–5.0)
INCS for AR treatment	448 (65.7)
Oral antihistamine for AR treatment	216 (31.7)
Comorbidities	
Chronic rhinosinusitis ^a	93 (13.6)
Nasal polyps ^a	48 (7.0)
OSA	82 (12.0)
OSA treated with CPAP	48 (7.0)
Risk of OSA ^c	75 (11.0)
GERD ^a	148 (21.7)
GERD diagnosed by GerdQ ^d	13 (1.9)
History of peptic ulcer	24 (3.5)
Depression and anxiety ^a	38 (5.6)
Depression by HADS screening	4 (0.6)
Anxiety by HADS screening	6 (0.9)
Food allergy ^a	71 (10.4)
Aspirin hypersensitivity ^a	51 (7.5)
Atopic dermatitis ^a	83 (12.2)
Urticaria ^a	109 (16.0)
Diabetes	73 (10.7)
Hypertension	179 (26.2)
Obesity	46 (6.7)
Coronary artery disease	19 (2.8)
Chronic kidney disease	17 (2.5)

Data shown as n (%) or median (IQR). ^aDiagnosis by clinician. ^bDefined as visual analog scale ≥ 5 points. ^cDefined as STOP-Bang scores ≥ 3 points. ^dDefined as GerdQ > 9 points. AR, Allergic rhinitis; ARIA, Allergic rhinitis and its impact on asthma; CPAP, Continuous positive airway pressure; GERD, Gastroesophageal reflux disease; GerdQ, Gastroesophageal reflux disease questionnaire; HADS, Hospital anxiety and depression scale; INCS, Intranasal corticosteroids; ISAAC, International Study of Asthma and Allergies in Childhood; and OSA, Obstructive sleep apnea.

history, coronary artery disease, OSA, and use of medium to high-dose ICS treatment. However, they showed higher proportions of aeroallergen sensitization, severe AR and urticaria, as well as better pulmonary functions (Table 6).

Elderly patients had a later age at asthma diagnosis, higher proportions of GERD, diabetes, hypertension, coronary artery disease, and chronic kidney disease, but lower pulmonary functions

TABLE 3 Factors associated with controlled asthma.

Variables	Controlled asthma* (n = 377)	Not well-controlled asthma* (n = 305)	p value
Age, years	58.0 (49.0–63.0)	55.0 (43.0–65.0)	0.018
Female sex	252 (67.0)	224 (73.4)	0.069
Body mass index, kg/m ²	24.6 (22.3–27.3)	25.0 (22.5–29.4)	0.028
Age at asthma diagnosis, years	38.0 (22.3–50.0)	35.0 (17.0–48.0)	0.081
Smoking history	53 (14.2)	44 (14.5)	0.897
Indoor pollution exposure	57 (15.1)	69 (22.6)	0.012
Pre-BD FEV ₁ , %predicted	81.0 (70.0–92.0)	77.0 (64.0–90.3)	0.006
Pre-BD FEV ₁ /FVC, %	73.8 (65.5–81.2)	73.3 (64.0–81.6)	0.843
Blood eosinophil, cells/ μ L	228.50 (120.70–416.00)	204.34 (73.15–472.20)	0.280
Serum total IgE, IU/mL	114.00 (44.20–286.00)	170.00 (110.76–557.00)	0.054
Aeroallergen sensitization	58 (15.4)	83 (27.2)	<0.001
AQLQ, total scores	105.00 (98.00–105.00)	83.50 (70.00–95.00)	<0.001
AR ^a	300 (80.0)	240 (79.2)	0.799
VAS for AR severity, points	1.00 (0.00–2.00)	3.00 (1.00–5.00)	<0.001
Severe AR	62 (16.4)	144 (47.2)	<0.001
Nasal polyp	18 (4.8)	30 (9.8)	0.010
Urticaria	45 (12.0)	64 (21.0)	0.001
Food allergy	27 (7.2)	44 (14.4)	0.002
GERD ^a	68 (18.1)	80 (26.2)	0.010
Depression and anxiety ^a	12 (3.2)	26 (8.6)	0.002
History of peptic ulcer	8 (2.1)	16 (5.3)	0.027
History of asthma exacerbations	19 (5.1)	75 (24.8)	<0.001
OSA	39 (10.4)	43 (14.1)	0.137
INCS for AR treatment	243 (64.5)	205 (67.2)	0.451
Medium to high-dose ICS for asthma treatment	133 (35.3)	196 (64.3)	<0.001

Data shown as n (%) or median (IQR). *Controlled asthma defined as ACT > 22, whereas not well-controlled asthma defined as ACT $\leq$ 22. ^aDiagnosis by clinician. ACT, Asthma Control Test; AQLQ, Asthma Quality of Life Questionnaire; AR, Allergic rhinitis; BD, Bronchodilator; FEV₁, Forced expiratory volume in 1 s; FVC, Forced expiratory volume; GERD, Gastroesophageal reflux disease; ICS, Inhaled corticosteroid; IgE, Immunoglobulin E; INCS, Intranasal corticosteroid; IU, International unit; kg, Kilogram; L, Liter; m, Meter; mL, Milliliter; OSA, Obstructive sleep apnea; VAS, Visual analog scale; and μ L, Microliter.

and proportions of AR and INCS use than younger patients (Table 7).

4 Discussion

This is a large multicenter study of correlation between asthma control, AR, and asthma-related comorbidities in Thailand. Our study revealed that AR was a common comorbidity (79% by clinician diagnosis) with asthma in Thai patients. The occurrence of AR in asthmatic patients has been addressed in previous large-scale studies and in the Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines (31–33). Our AR prevalence in asthmatic patients (79%) is higher than studies in Saudi Arabia (33%) (34), Iran (47%) (35), Japan (67%) (36), Italy (60%) (37), and France (66%) (38) but is lower than the United States (94%) (39). There was concordance between the ISAAC-definition of AR and clinical diagnoses, indicating that diagnosis by clinicians was as reliable as the standard questionnaire used in epidemiological surveys. The most common AR symptoms

classified by the ISAAC questionnaire reports were “nose symptoms ever” and “nose symptoms within 12 months” due to perennial AR. The prevalence of eye symptoms in our study (42%) was double the prevalence in a previous study in Thailand by Vichyanond et al. (6). These results can be explained by increased physician awareness of rhinitis coexisting with asthma (15). In addition, climate change and air pollution in Thailand aggravate AR, asthma, and other chronic respiratory diseases (40).

The majority of Thai asthmatic patients had mild AR, according to the ARIA criteria and VAS scores for symptom severity. The prevalence of mild AR in our study was comparable to the prevalence in two other studies (41, 42). This may be because the majority of AR patients were already treated with either intranasal corticosteroid or antihistamine. A relationship between rhinitis severity according to ARIA classification and medical treatment for AR and asthma was shown in a previous study by Antonicelli et al. (43). The patients in our study had controlled asthma according to ACT scores and had well-preserved lung function. The frequency of asthma exacerbation in our study (8% ED visits) was much lower than the frequency in a

TABLE 4 Correlation between severity of allergic rhinitis and asthma characteristics.

Parameters	Severity of allergic rhinitis (VAS scores)	
	<i>R</i>	<i>p</i> value
ACT scores	−0.461	<0.001
AQLQ total scores	−0.512	<0.001
AQLQ symptom	−0.487	<0.001
AQLQ activity	−0.355	<0.001
AQLQ emotion	−0.427	<0.001
AQLQ environment	−0.453	<0.001
HADS anxiety subscale	0.357	0.006
HADS depression subscale	0.401	0.002
Pre-BD FEV ₁ (% predicted)	−0.037	0.368
Pre-BD FEV ₁ /FVC (%)	0.020	0.635
Total IgE, IU/mL	0.246	0.023

ACT, Asthma Control Test; AQLQ, Asthma Quality of Life Questionnaire; BD, Bronchodilator; FEV₁, Forced expiratory volume in 1 s; FVC, Forced expiratory volume; HADS, Hospital anxiety and depression scale; IgE, Immunoglobulin E; IU, International unit; mL, Milliliter; and VAS, Visual analog scale.

TABLE 5 Multiple logistic regression analysis for factors associated with severe allergic rhinitis in patients with asthma.

Variables	Regression coefficients	95% CI of coefficients	<i>p</i> value
Intercept	1.359	0.439, 2.279	0.009
ACT scores	0.553	0.028, 0.107	0.004
AQLQ scores	−0.898	−0.035, −0.016	<0.001
Pre-BD FEV ₁ /FVC (%)	−0.672	−0.012, −0.005	0.001

ACT, Asthma Control Test; AQLQ, Asthma Quality of Life Questionnaire; BD, Bronchodilator; FEV₁, Forced expiratory volume in 1 s; and FVC, Forced expiratory volume.

previous survey by Boonsawat et al. (44) (22% ED visits) in which less inhaled corticosteroid-containing regimens were used. The inverse correlation between AR and spirometry in Thai asthmatic patients resembles previous studies. They demonstrated that lung function abnormalities detected by spirometry in AR patients without clinical symptoms of asthma are directly correlated to rhinitis severity (45, 46). The frequency and severity of AR increased with the severity of asthma (33). Moreover, our results demonstrated that lower lung function determined by FEV₁ was associated with not-well-controlled asthma. The effects of AR treatment and asthma treatment on the severity of both diseases have been shown. The most commonly prescribed rhinitis medication in our Thai asthmatics was intranasal corticosteroid, which was comparable to Western world studies (42, 47).

Severe AR determined by VAS score affected asthma control measured by ACT and asthma-related quality of life measured by AQLQ in our study. Low scores of symptom, activity, emotion, and environment domains of AQLQ were negatively influenced by more severe rhinitis. Our study also showed moderate negative correlations between AR severity and AQLQ score. When focusing on each domain in AQLQ, moderate correlations were found in the symptoms, emotional function, and environmental exposure domains, while a

weak correlation was found in the activity limitation domain. The correlation between AR severity and AQLQ is possibly an indirect effect from AR and asthma or possibly due to overlap in the quality-of-life questionnaire as some questions are not specific to asthma morbidities but could be due to AR or other comorbidities (9, 48). Our study showed significantly negative correlations between AR severity by VAS score and ACT scores. This finding was similar to a previous report by Acevedo-Prado et al. (49). They found significant correlation between asthma symptoms and rhinitis severity in asthmatic patients.

Our study revealed a predominant proportion of females (70%), potentially explained by hormonal effects. Estrogen contributes to the inflammatory pathway by stimulating hormone receptors on dendritic cells, mast cells, CD4+ T lymphocytes (Th2), and eosinophils, possibly contributing to a higher number of asthma exacerbations in females (50). This effect might explain the higher percentage of aeroallergen sensitization observed in female asthmatic patients in our study. Additionally, we observed more severe AR and urticaria in this group. These factors might contribute to a worse asthma-related quality of life in female asthmatic patients.

Our study showed that Thai asthmatic patients have type-2 high asthma with high blood eosinophil levels and allergy driven diseases. Serum total IgE level generally tends to be higher in patients with allergy diseases compared with non-allergic individuals (51). Weak correlation between AR severity and IgE level was demonstrated in our study. Our findings were similar to a previous large population-based study which showed correlation between increased total IgE levels and asthma but not correlation between IgE levels and AR (52).

Other asthma-related comorbidities were addressed in our study including atopic dermatitis, eczema, chronic rhinosinusitis, nasal polyps, and food allergies. However, non-allergic comorbidities, for instance GERD, and anxiety and depression were commonly seen in Thai asthmatic patients. Other conditions which affect asthma control, i.e., age, BMI, AR severity, indoor pollution exposure, aeroallergen sensitization, nasal polyp, urticaria, food allergy, GERD, depression and anxiety, peptic ulcer, asthma exacerbations, and lung function, need to be considered. However, under-dose of ICS treatment is pivotal for achieving asthma control. These findings emphasize the roles of multimorbidity in asthma, association with allergic diseases, and the symptom burden (53). The interaction between GERD, OSA, and asthma is robust and complex (54). AR has been shown to be associated and it increases the risk of developing OSA. The putative mechanisms are increased airway resistance from nasal blockage and reduced pharyngeal diameter from breathing through the mouth (54). The prevalence of OSA in Thai asthmatic patients (12%) in our study is lower than a meta-analysis (49%) by Kong et al. (55). It might be because Thai asthmatic patients have near normal BMI leading to lower risk of OSA. Thai patients with not-well-controlled asthma had higher BMI than those with well-controlled asthma. These complexities of asthma and related comorbidities must be properly managed in specific clinical contexts.

Other important comorbidities in asthma are depression and anxiety. These were not uncommon in Thai asthmatic and AR patients in our study. A previous study by Rodrigues et al. (56) demonstrated that moderate/severe AR correlated with anxiety and depression scores by HADS. Our study showed higher percentage of anxiety and depression (higher HADS scores) in patients with not-well-controlled asthma. Furthermore, there was a significantly positive correlation between AR severity by VAS scores and anxiety or depression scores.

TABLE 6 Differences in clinical characteristics between females and males with asthma.

Variables	Female (<i>n</i> = 477)	Male (<i>n</i> = 205)	<i>p</i> value
Age, years	57.0 (45.0–63.5)	58.0 (48.5–64.0)	0.208
Body mass index, kg/m ²	24.5 (22.0–27.9)	25.2 (23.0–28.9)	0.015
Smoking history	19 (4.0)	78 (38.0)	<0.001
Indoor pollution exposure	88 (18.4)	38 (18.5)	0.978
Age at asthma diagnosis, years	36.0 (21.0–49.0)	38.0 (20.0–50.0)	0.869
Controlled asthma*	253 (53.0)	124 (60.5)	0.073
Pre-BD FEV ₁ , %predicted	81.0 (68.0–92.2)	78.0 (63.4–90.5)	0.042
Pre-BD FEV ₁ /FVC, %	75.6 (66.1–83.0)	70.6 (59.9–78.0)	<0.001
Blood eosinophil, cells/ μ L	190.06 (80.56–437.47)	285.30 (160.80–451.82)	0.005
Serum total IgE, IU/mL	147.00 (51.45–505.62)	245.00 (134.00–519.00)	0.091
Aeroallergen sensitization	110 (23.1)	31 (15.1)	0.019
AQLQ, total scores	96.00 (81.00–105.00)	101.00 (91.00–105.00)	<0.001
AR ^a	380 (79.7)	160 (78.0)	0.726
VAS for AR severity, points	2.00 (0.00–5.00)	2.00 (0.00–4.00)	0.200
Severe AR	155 (32.5)	51 (24.9)	0.034
Nasal polyp	31 (6.5)	17 (8.3)	0.405
Urticaria	92 (19.3)	17 (8.4)	<0.001
Food allergy	51 (10.7)	20 (9.8)	0.728
GERD ^a	107 (22.5)	41 (20.0)	0.472
Depression and anxiety ^a	30 (6.3)	8 (3.9)	0.209
History of peptic ulcer	20 (4.2)	4 (2.0)	0.146
Diabetes	47 (9.9)	26 (12.7)	0.281
Hypertension	122 (25.6)	57 (27.8)	0.544
Coronary artery disease	9 (1.9)	10 (4.9)	0.030
Chronic kidney disease	9 (1.9)	8 (3.9)	0.117
Obesity	28 (5.9)	18 (8.8)	0.169
History of asthma exacerbations	73 (15.4)	21 (10.2)	0.073
OSA	47 (9.9)	35 (17.1)	0.008
INCS for AR treatment	312 (65.4)	136 (66.3)	0.814
Medium to high-dose ICS for asthma treatment	212 (44.4)	117 (57.1)	0.002

Data shown as *n* (%) or median (IQR). *Controlled asthma defined as ACT > 22, whereas not well-controlled asthma defined as ACT $\leq$ 22. ^aDiagnosis by clinician. ACT, Asthma Control Test; AQLQ, Asthma Quality of Life Questionnaire; AR, Allergic rhinitis; BD, Bronchodilator; FEV₁, Forced expiratory volume in 1 s; FVC, Forced expiratory volume; GERD, Gastroesophageal reflux disease; ICS, Inhaled corticosteroid; IgE, Immunoglobulin E; INCS, Intranasal corticosteroid; IU, International unit; kg, Kilogram; L, Liter; m, Meter; mL, Milliliter; OSA, Obstructive sleep apnea; VAS, Visual analog scale; and μ L, Microliter.

The relationship between AR severity and asthma-related parameters supports the concept of united airway disease and the link between quality of life and mental disorders. When lower airway-related symptoms are observed in AR patients, careful evaluation is strongly encouraged (57). Careful clinical evaluation and monitoring of AR patients are essential for achieving asthma control. This has been addressed in global and national asthma recommendations, including in Thailand (2, 3, 58). The prevalence and the importance of AR coexisting with asthma and other comorbidities must be addressed.

This study has some limitations. Firstly, some patient data might be missing from the multicenter study, therefore some results might not be accurate. Secondly, this study was conducted during the COVID-19 pandemic. This situation might have affected clinical

outcomes such as asthma exacerbation rates, which might be lower than expected due to preventions of respiratory infection (e.g., mask wearing). Thirdly, according to the study, patients were examined only once, leading to the possibility of informational bias. It is possible that during the examination, patients did not exhibit signs of AR, and there is no information about episodes of such comorbidity in the period preceding the examination. Fourthly, the study exclusively enrolled adults, excluding children. Therefore, the findings are limited in their applicability to pediatric patients with asthma. Lastly, the study recruited patients only from tertiary hospitals; hence, data on disease severity and special treatment might be biased in selection. A longer prospective study is needed to determine long-term correlations between asthma and asthma comorbidities, including allergic diseases. For future perspectives, we believe there are potential advancements

TABLE 7 Differences in characteristics between younger and elderly patients with asthma.

Variables	Younger (n = 520)	Elderly (n = 162)	p value
Age, years	53.0 (43.0–59.0)	71.0 (68.0–75.3)	<0.001
Female sex	112 (69.1)	365 (70.2)	0.798
Body mass index, kg/m ²	24.8 (22.4–28.3)	24.4 (22.6–27.4)	0.372
Smoking history	69 (13.4)	28 (17.4)	0.204
Indoor pollution exposure	88 (16.9)	38 (23.5)	0.061
Age at asthma diagnosis, years	30.0 (16.0–44.0)	51.0 (12.3–66.0)	<0.001
Controlled asthma*	292 (56.2)	85 (52.5)	0.410
Pre-BD FEV ₁ , %predicted	81.07 (69.00–93.00)	73.00 (62.00–87.00)	<0.001
Pre-BD FEV ₁ /FVC, %	76.68 (67.00–83.00)	67.65 (57.75–73.99)	<0.001
Blood eosinophil, cells/ μ L	219.43 (84.05–443.35)	249.60 (121.53–426.72)	0.220
Serum total IgE, IU/mL	151.87 (67.85–443.25)	194.50 (82.35–679.00)	0.550
Aeroallergen sensitization	104 (20.0)	37 (22.8)	0.436
AQLQ, total scores	98.00 (83.00–105.00)	96.00 (85.00–103.00)	0.096
AR ^a	441 (85.3)	99 (61.5)	<0.001
VAS for AR severity, points	2.00 (0.00–5.00)	2.00 (0.00–4.50)	0.673
Severe AR	158 (30.4)	47 (29.0)	0.739
Nasal polyp	32 (6.2)	16 (9.9)	0.107
Urticaria	82 (15.8)	27 (16.9)	0.739
Food allergy	51 (9.8)	20 (12.3)	0.360
GERD ^a	96 (18.5)	52 (32.3)	<0.001
Depression and anxiety ^a	29 (5.6)	9 (5.6)	0.983
History of peptic ulcer	14 (2.7)	10 (6.2)	0.037
Diabetes	34 (6.6)	39 (24.2)	<0.001
Hypertension	95 (18.3)	84 (51.9)	<0.001
Coronary artery disease	10 (1.9)	9 (5.6)	0.015
Chronic kidney disease	7 (1.4)	10 (6.2)	0.001
Obesity	7 (4.3)	39 (7.5)	0.162
OSA	59 (11.4)	23 (14.2)	0.334
History of asthma exacerbations	77 (14.9)	17 (10.6)	0.175
INCS for AR treatment	369 (71.0)	79 (48.8)	<0.001
Medium to high-dose ICS for asthma treatment	242 (46.5)	87 (53.7)	0.111

Data shown as n (%) or median (IQR). *Controlled asthma defined as ACT > 22, whereas not well-controlled asthma defined as ACT $\leq$ 22. ^aDiagnosis by clinician.

ACT, Asthma Control Test; AQLQ, Asthma Quality of Life Questionnaire; AR, Allergic rhinitis; BD, Bronchodilator; FEV₁, Forced expiratory volume in 1 s; FVC, Forced expiratory volume; GERD, Gastroesophageal reflux disease; ICS, Inhaled corticosteroid; IgE, Immunoglobulin E; INCS, Intranasal corticosteroid; IU, International unit; kg, Kilogram; L, Liter; m, Meter, mL, Milliliter; OSA, Obstructive sleep apnea; VAS, Visual analog scale; and μ L, microliter.

in the management of asthma and allergic rhinitis comorbidities. Personalized medicine may lead to more targeted treatments for individuals with asthma and allergic rhinitis in general practice. Meanwhile, a more holistic approach to managing asthma and AR may emerge as comprehensive patient management. This approach involves not only symptom management but also addressing underlying causes and contributing factors.

5 Conclusion

Allergic rhinitis is prevalent in Thai asthmatic patients. AR severity is associated with asthma control, quality of life, and

pulmonary function. Several other comorbidities and parameters are also related to asthma control. Comprehensive patient care, including assessment, treatment, monitoring, and environmental control, is essential for patients with uncontrolled asthma, particularly when coexisting with conditions such as obesity, severe AR, nasal polyp, urticaria, food allergy, GERD, peptic ulcer, and psychiatric problems.

Data availability statement

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

Ethics statement

The studies involving humans were approved by the institutional committee on human research in each site of patient recruitment, in full compliance with international guidelines such as the Declaration of Helsinki, the Belmont Report, CIOMS Guidelines, and the International Conference on Harmonization-Good Clinical Practice (ICH-GCP). The studies were conducted in accordance with the local legislation and institutional requirements. The participants provided their written informed consent to participate in this study.

Author contributions

TS: Conceptualization, Data curation, Formal analysis, Funding acquisition, Methodology, Software, Supervision, Validation, Visualization, Writing – review & editing. NS: Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Validation, Visualization, Writing – review & editing. TK: Conceptualization, Data curation, Investigation, Methodology, Validation, Visualization, Writing – original draft, Writing – review & editing. WB: Conceptualization, Data curation, Investigation, Supervision, Validation, Visualization, Writing – review & editing. WM: Conceptualization, Data curation, Methodology, Visualization, Writing – review & editing. NC: Conceptualization, Investigation, Methodology, Visualization, Writing – review & editing. CC: Conceptualization, Formal analysis, Investigation, Methodology, Validation, Visualization, Writing – review & editing. AA: Conceptualization, Formal analysis, Methodology, Validation, Visualization, Writing – review & editing. HK: Conceptualization, Validation, Visualization, Writing – review & editing. KK: Conceptualization, Supervision, Validation, Visualization, Writing – review & editing. MK: Conceptualization, Data curation, Investigation, Methodology, Validation, Visualization, Writing – review & editing. MS: Conceptualization, Validation, Visualization, Writing – review & editing. NO-A: Conceptualization, Validation, Visualization, Writing – review & editing. TR: Conceptualization, Validation, Visualization, Writing – review & editing. SS: Conceptualization, Validation, Visualization, Writing – review & editing. ST: Conceptualization, Data curation, Investigation, Project administration, Resources, Validation, Visualization, Writing – review & editing. TG: Conceptualization,

Validation, Visualization, Writing – review & editing. KJ: Data curation, Formal analysis, Project administration, Software, Visualization, Writing – review & editing. OP: Conceptualization, Funding acquisition, Investigation, Methodology, Project administration, Supervision, Validation, Visualization, Writing – original draft, Writing – review & editing.

Funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This work was supported by Thammasat University Research Unit in Allergy and Respiratory Medicine, Thailand (grant number 67.04.2/0904) and Thai Asthma Council and Association (TAC), Thailand (grant number 341/2564).

Acknowledgments

The authors would like to thank Michael Jan Everts, Faculty of Medicine, Thammasat University, for proofreading this manuscript. This work was supported by Thammasat University Research Unit in Allergy and Respiratory Medicine, Thailand and Thai Asthma Council and Association (TAC), Thailand.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

1. Global Initiative for Asthma (2023). Global strategy for asthma management and prevention. Available at: <https://ginasthma.org/>
2. Reddel HK, Bacharier LB, Bateman ED, Brightling CE, Brusselle GG, Buhl R, et al. Global initiative for asthma strategy 2021: executive summary and rationale for key changes. *Eur Respir J*. (2022) 59:2102730. doi: 10.1183/13993003.02730-2021
3. Bousquet J, Schünemann HJ, Togias A, Bachert C, Erhola M, Hellings PW, et al. Next-generation allergic rhinitis and its impact on asthma (ARIA) guidelines for allergic rhinitis based on grading of recommendations assessment, development and evaluation (GRADE) and real-world evidence. *J Allergy Clin Immunol*. (2020) 145:70–80.e3. doi: 10.1016/j.jaci.2019.06.049
4. Pawankar R, Bunnag C, Chen Y, Fukuda T, Kim YY, Le LT, et al. Allergic rhinitis and its impact on asthma update (ARIA 2008)--western and Asian-Pacific perspective. *Asian Pac J Allergy Immunol*. (2009) 27:237–43.
5. Vichayanond P, Jirapongsananuruk O, Visitsuntorn N, Tuchinda M. Prevalence of asthma, rhinitis and eczema in children from the Bangkok area using the ISAAC (international study for asthma and allergy in children) questionnaires. *J Med Assoc Thai*. (1998) 81:175–84.
6. Vichayanond P, Sunthornchart S, Singhirannusorn V, Ruangrat S, Kaewsomboon S, Visitsunthorn N. Prevalence of asthma, allergic rhinitis and eczema among university students in Bangkok. *Respir Med*. (2002) 96:34–8. doi: 10.1053/rmed.2001.1202
7. Valovirta E, Pawankar R. Survey on the impact of comorbid allergic rhinitis in patients with asthma. *BMC Pulm Med*. (2006) 6:S3. doi: 10.1186/1471-2466-6-s1-s3
8. Trakultivakorn M, Sangsupawanich P, Vichayanond P. Time trends of the prevalence of asthma, rhinitis and eczema in Thai children-ISAAC (international study of asthma and allergies in childhood) phase three. *J Asthma*. (2007) 44:609–11. doi: 10.1080/02770900701540119
9. Sritipsukho P, Satdhabudha A, Nanthapaisal S. Effect of allergic rhinitis and asthma on the quality of life in young Thai adolescents. *Asian Pac J Allergy Immunol*. (2015) 33:222–6. doi: 10.12932/AP0548.33.3.2015
10. Thanaviratnanich S, Cho SH, Ghoshal AG, Muttalif A, Lin HC, Pothirath C, et al. Burden of respiratory disease in Thailand: results from the APBORD observational study. *Medicine (Baltimore)*. (2016) 95:e4090. doi: 10.1097/MD.0000000000004090
11. Ghoshal AG, Ravindran GD, Gangwal P, Rajadhyaksha G, Cho SH, Muttalif AR, et al. The burden of segregated respiratory diseases in India and the quality of care in

these patients: results from the Asia-Pacific burden of respiratory diseases study. *Lung India*. (2016) 33:611–9. doi: 10.4103/0970-2113.192878

12. Savouire M, Bousquet J, Jaakkola JJK, Jaakkola MS, Jacquemin B, Nadif R. Worldwide prevalence of rhinitis in adults: a review of definitions and temporal evolution. *Clin Transl Allergy*. (2022) 12:e12130. doi: 10.1002/ct2.12130

13. Thompson PJ, Salvi S, Lin J, Cho YJ, Eng P, Abdul Manap R, et al. Insights, attitudes and perceptions about asthma and its treatment: findings from a multinational survey of patients from 8 Asia-Pacific countries and Hong Kong. *Respirology*. (2013) 18:957–67. doi: 10.1111/resp.12137

14. Boonsawat W, Thompson PJ, Zaeoui U, Samosorn C, Acar G, Faruqi R, et al. Survey of asthma management in Thailand—the asthma insight and management study. *Asian Pac J Allergy Immunol*. (2015) 33:14–20. doi: 10.12932/AP0473.33.1.2015

15. Bunupuradah T, Siriakorn S, Hinds D, Shantakumar S, Mulgirigama A, Aggarwal B. A survey of management practices in coexistent allergic rhinitis and asthma (Asia-Pacific survey of physicians on asthma and allergic rhinitis): results from Thailand. *Asia Pac Allergy*. (2019) 9:e24. doi: 10.5415/apallergy.2019.9.e24

16. Althoff MD, Ghinea A, Wood LG, Holguin F, Sharma S. Asthma and three colinear comorbidities: obesity, OSA, and GERD. *J Allergy Clin Immunol Pract*. (2021) 9:3877–84. doi: 10.1016/j.jaip.2021.09.003

17. Cardet JC, Bulkhi AA, Lockey RF. Nonrespiratory comorbidities in asthma. *J Allergy Clin Immunol Pract*. (2021) 9:3887–97. doi: 10.1016/j.jaip.2021.08.027

18. Paoletti G, Melone G, Ferri S, Puggioni F, Baiardini I, Racca F, et al. Gastroesophageal reflux and asthma: when, how, and why. *Curr Opin Allergy Clin Immunol*. (2021) 21:52–8. doi: 10.1097/ACI.0000000000000705

19. Prasad B, Nyenhuis SM, Imayama I, Siddiqi A, Teodorescu M. Asthma and obstructive sleep apnea overlap: what has the evidence taught us? *Am J Respir Crit Care Med*. (2020) 201:1345–57. doi: 10.1164/rccm.201810-1838TR

20. Pawankar R, Mori S, Ozu C, Kimura S. Overview on the pathomechanisms of allergic rhinitis. *Asia Pac Allergy*. (2011) 1:157–67. doi: 10.5415/apallergy.2011.1.3.157

21. Niyatiwanchai N, Chaiwong W, Pothirat C. The validity and reliability of the Thai version of the asthma control test. *Asian Pac J Allergy Immunol*. (2021). doi: 10.12932/AP-130820-0940

22. Nathan RA, Sorkness CA, Kosinski M, Schatz M, Li JT, Marcus P, et al. Development of the asthma control test: a survey for assessing asthma control. *J Allergy Clin Immunol*. (2004) 113:59–65. doi: 10.1016/j.jaci.2003.09.008

23. Juniper EF, Buist AS, Cox FM, Ferrie PJ, King DR. Validation of a standardized version of the asthma quality of life questionnaire. *Chest*. (1999) 115:1265–70. doi: 10.1378/chest.115.5.1265

24. Lertsinudom S, Johns NP, Chanthawong S, Boonsawat W, Samosorn C. Validity and reliability of the Thai Mini asthma quality of life questionnaire. *J Med Assoc Thai*. (2010) 93:373–7.

25. Sapsaprang S, Setabutr D, Kulalert P, Temboonnark P, Poachanukoon O. Evaluating the impact of allergic rhinitis on quality of life among Thai students. *Int Forum Allergy Rhinol*. (2015) 5:801–7. doi: 10.1002/alr.21540

26. Prasithsirikul W, Chongthawonsatid S, Ohata PJ, Keadpudsa S, Klinbuayaem V, Rerksirikul P, et al. Depression and anxiety were low amongst virally suppressed, long-term treated HIV-infected individuals enrolled in a public sector antiretroviral program in Thailand. *AIDS Care*. (2017) 29:299–305. doi: 10.1080/09540121.2016.1201194

27. Bjelland I, Dahl AA, Haug TT, Neckelmann D. The validity of the hospital anxiety and depression scale. An updated literature review. *J Psychosom Res*. (2002) 52:69–77. doi: 10.1016/S0022-3999(01)00296-3

28. Jonasson C, Wernersson B, Hoff DA, Hatlebakk JG. Validation of the GerdQ questionnaire for the diagnosis of gastro-oesophageal reflux disease. *Aliment Pharmacol Ther*. (2013) 37:564–72. doi: 10.1111/apt.12204

29. Sangkum L, Wathanavaha C, Tantrakul V, Pothong M, Karnjanarachata C. Modified STOP-bang for predicting perioperative adverse events in the Thai population. *BMC Anesthesiol*. (2021) 21:132. doi: 10.1186/s12871-021-01347-0

30. Graham BL, Steenbruggen I, Miller MR, Barjaktarevic IZ, Cooper BG, Hall GL, et al. Standardization of spirometry 2019 update. An official American Thoracic Society and European Respiratory Society technical statement. *Am J Respir Crit Care Med*. (2019) 200:e70–88. doi: 10.1164/rccm.201908-1590ST

31. Greisner WA 3rd, Settupane RJ, Settupane GA. Co-existence of asthma and allergic rhinitis: a 23-year follow-up study of college students. *Allergy Asthma Proc*. (1998) 19:185–8. doi: 10.2500/108854198778557836

32. Brożek JL, Bousquet J, Agache I, Agarwal A, Bachert C, Bosnic-Anticevich S, et al. Allergic rhinitis and its impact on asthma (ARIA) guidelines-2016 revision. *J Allergy Clin Immunol*. (2017) 140:950–8. doi: 10.1016/j.jaci.2017.03.050

33. Magnan A, Meunier JP, Saugnac C, Gasteau J, Neukirch F. Frequency and impact of allergic rhinitis in asthma patients in everyday general medical practice: a French observational cross-sectional study. *Allergy*. (2008) 63:292–8. doi: 10.1111/j.1398-9995.2007.01584.x

34. Alrasheedi SM, Alkhalifah KM, Alnasyan S, Alwattban RR, Alsubhi RA, Alsamani RI, et al. The prevalence and impact of allergic rhinitis on asthma exacerbations in

asthmatic adult patients in the Qassim region of Saudi Arabia: a cross-sectional study. *Cureus*. (2023) 15:e44997. doi: 10.7759/cureus.44997

35. Shokouhi Shoorasti R, Pourpak Z, Fazlollahi MR, Kazemnejad A, Nadali F, Ebadi Z, et al. The prevalence of allergic rhinitis, allergic conjunctivitis, atopic dermatitis and asthma among adults of Tehran. *Iran J Public Health*. (2018) 47:1749–55.

36. Ohta K, Bousquet PJ, Aizawa H, Akiyama K, Adachi M, Ichinose M, et al. Prevalence and impact of rhinitis in asthma. SACRA, a cross-sectional nation-wide study in Japan. *Allergy*. (2011) 66:1287–95. doi: 10.1111/j.1398-9995.2011.02676.x

37. Bugiani M, Carosso A, Migliore E, Piccioni P, Corsico A, Olivieri M, et al. Allergic rhinitis and asthma comorbidity in a survey of young adults in Italy. *Allergy*. (2005) 60:165–70. doi: 10.1111/j.1398-9995.2005.00659.x

38. Demoly P, Crampette L, Daures JP. National survey on the management of rhinopathies in asthma patients by French pulmonologists in everyday practice. *Allergy*. (2003) 58:233–8. doi: 10.1034/j.1398-9995.2003.00051.x

39. Togias A. Unique mechanistic features of allergic rhinitis. *J Allergy Clin Immunol*. (2000) 105:S599–604. doi: 10.1067/mai.2000.106885

40. Eguluz-Gracia I, Mathioudakis AG, Bartel S, Vijverberg SJH, Fuertes E, Comberlati P, et al. The need for clean air: the way air pollution and climate change affect allergic rhinitis and asthma. *Allergy*. (2020) 75:2170–84. doi: 10.1111/all.14177

41. Lee CH, Jang JH, Lee HJ, Kim IT, Chu MJ, Kim CD, et al. Clinical characteristics of allergic rhinitis according to allergic rhinitis and its impact on asthma guidelines. *Clin Exp Otorhinolaryngol*. (2008) 1:196–200. doi: 10.3342/ceo.2008.1.4.196

42. Demoly P, Bousquet PJ, Mesbah K, Bousquet J, Devillier P. Visual analogue scale in patients treated for allergic rhinitis: an observational prospective study in primary care: asthma and rhinitis. *Clin Exp Allergy*. (2013) 43:881–8. doi: 10.1111/cea.12121

43. Antonicelli L, Micucci C, Voltolini S, Senna GE, Di Blasi P, Visonà G, et al. Relationship between ARIA classification and drug treatment in allergic rhinitis and asthma. *Allergy*. (2007) 62:1064–70. doi: 10.1111/j.1398-9995.2007.01470.x

44. Boonsawat W, Charoenphan P, Kiatboonsri S, Wongtim S, Viriyachaiyo V, Pothirat C, et al. Survey of asthma control in Thailand. *Respirology*. (2004) 9:373–8. doi: 10.1111/j.1440-1843.2004.00584.x

45. Mohammad Y, Shaaban R, Ibrahim M, Ismail M. Lung function changes in non-asthmatic allergic rhinitis patients: a case series. *Prim Care Respir J*. (2011) 20:454–6. doi: 10.4104/pcrj.2011.00089

46. Saranz RJ, Lozano A, Valero A, Lozano NA, Bovina Martijena MD, Agresta F, et al. Impact of rhinitis on lung function in children and adolescents without asthma. *Allergol Immunopathol (Madr)*. (2016) 44:556–62. doi: 10.1016/j.aller.2016.04.006

47. Gani F, Lombardi C, Barrocu L, Landi M, Ridolo E, Bugiani M, et al. The control of allergic rhinitis in real life: a multicenter cross-sectional Italian study. *Clin Mol Allergy*. (2018) 16:4. doi: 10.1186/s12948-018-0082-y

48. Elkholy MM, Khedr MH, Halawa A, Elbaramawy A. Impact of allergic rhinitis on quality of life in patients with bronchial asthma. *Int J Health Sci*. (2012) 6:194–202.

49. Acevedo-Prado A, Seoane-Pillado T, López-Silvarrey-Varela A, Salgado FJ, Cruz MJ, Faraldo-García A, et al. Association of rhinitis with asthma prevalence and severity. *Sci Rep*. (2022) 12:6389. doi: 10.1038/s41598-022-10448-w

50. Koper I, Hufnagl K, Ehmann R. Gender aspects and influence of hormones on bronchial asthma—secondary publication and update. *World Allergy Organ J*. (2017) 10:46. doi: 10.1186/s40413-017-0177-9

51. Stone KD, Prussin C, Metcalfe DD. IgE, mast cells, basophils, and eosinophils. *J Allergy Clin Immunol*. (2010) 125:S73–80. doi: 10.1016/j.jaci.2009.11.017

52. Burrows B, Martinez FD, Halonen M, Barbee RA, Cline MG. Association of asthma with serum IgE levels and skin-test reactivity to allergens. *N Engl J Med*. (1989) 320:271–7. doi: 10.1056/NEJM198902023200502

53. Blöndal V, Malinovschi A, Sundbom F, James A, Middelvelde R, Franklin KA, et al. Multimorbidity in asthma, association with allergy, inflammatory markers and symptom burden, results from the Swedish GA(2) LEN study. *Clin Exp Allergy*. (2021) 51:262–72. doi: 10.1111/cea.13759

54. Chirakalwasan N, Ruxrungtham K. The linkage of allergic rhinitis and obstructive sleep apnea. *Asian Pac J Allergy Immunol*. (2014) 32:276–86.

55. Kong DL, Qin Z, Shen H, Jin HY, Wang W, Wang ZF. Association of obstructive sleep apnea with asthma: a meta-analysis. *Sci Rep*. (2017) 7:4088. doi: 10.1038/s41598-017-04446-6

56. Rodrigues J, Pinto JV, Alexandre PL, Sousa-Pinto B, Pereira AM, Raemdonck K, et al. Allergic rhinitis seasonality, severity, and disease control influence anxiety and depression. *Laryngoscope*. (2023) 133:1321–7. doi: 10.1002/lary.30318

57. Saranz RJ, Lozano A, Lozano NA, Ponzio MF, Cruz AA. Subclinical lower airways correlates of chronic allergic and non-allergic rhinitis. *Clin Exp Allergy*. (2017) 47:988–97. doi: 10.1111/cea.12938

58. Kawatawong T, Sangasapaviriya A, Saiphoklang N, Oer-Areemitr N, Sriprasart T, Kamalaporin H, et al. Guidelines for the management of asthma in adults: evidence and recommendations. *Asian Pac J Allergy Immunol*. (2022) 40:1–21. doi: 10.12932/AP-210421-1118